Vanda Pharmaceuticals (NASDAQ:VNDA) Stock: Insider Charles Cliff Duncan Acquires 5,803 Shares

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Charles Duncan bought 5,803 shares of the stock in a transaction on Thursday, November 5th. The shares were bought at an average price of $3.80 per share, with a total value of $22,051.40. Following the acquisition, the director owned 108,701 shares of the company’s stock, valued at $413,063.80. This trade represents a 5.64% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Charles Cliff Duncan also recently made the following trade(s):

• On Wednesday, November 4th, Charles Duncan purchased 3,447 shares of Vanda Pharmaceuticals stock. The stock was purchased at an average cost of $3.82 per share, with a total value of $13,167.54.
• On Tuesday, November 3rd, Charles Duncan bought 750 shares of Vanda Pharmaceuticals stock. The stock was bought at an average cost of $3.80 per share, with a total value of $2,850.00.

Vanda Pharmaceuticals Stock Up 6.4%

VNDA opened at $3.82 on Friday. Vanda Pharmaceuticals Inc. has a 12-month low of $3.57 and a 12-month high of $9.94. The firm’s fifty day moving average price is $4.63 and its 200 day moving average price is $6.12. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.31. The firm had revenue of $69.81 million during the quarter, compared to analyst estimates of $69.20 million. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 62.70%. On average, equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -2.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on VNDA. Wall Street Zen upgraded shares of Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 31st. B. Riley Financial reiterated a “buy” rating and set a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Oppenheimer started coverage on Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective for the company. HC Wainwright reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, October 15th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Vanda Pharmaceuticals in the 2nd quarter worth about $46,841,000. Renaissance Technologies LLC raised its position in shares of Vanda Pharmaceuticals by 11.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock valued at $25,979,000 after buying an additional 378,598 shares during the period. State Street Corp increased its stake in Vanda Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock valued at $21,520,000 after purchasing an additional 500,843 shares during the last quarter. AIGH Capital Management LLC boosted its position in shares of Vanda Pharmaceuticals by 37.6% in the 1st quarter. AIGH Capital Management LLC now owns 2,750,000 shares of the biopharmaceutical company’s stock worth $19,002,000 after buying an additional 751,569 shares in the last quarter. Finally, Quantinno Capital Management LP increased its holdings in Vanda Pharmaceuticals by 25.0% during the 1st quarter. Quantinno Capital Management LP now owns 327,193 shares of the biopharmaceutical company’s stock worth $2,261,000 after purchasing an additional 65,391 shares during the last quarter. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.